Shore Capital restated their buy rating on shares of Consort Medical (LON:CSRT) in a research note released on Monday, ThisIsMoney.Co.Uk reports.
CSRT has been the subject of a number of other reports. Royal Bank of Canada increased their price target on shares of Lululemon Athletica to $200.00 and gave the stock an outperform rating in a research note on Thursday, June 13th. Numis Securities increased their price target on shares of from GBX 532 ($6.95) to GBX 705 ($9.21) and gave the stock a buy rating in a research note on Thursday, June 6th.
CSRT stock opened at GBX 774 ($10.11) on Monday. Consort Medical has a 1 year low of GBX 700 ($9.15) and a 1 year high of GBX 1,270 ($16.59). The company has a market capitalization of $382.08 million and a P/E ratio of 36.51. The business has a 50-day moving average of GBX 874.64. The company has a current ratio of 1.63, a quick ratio of 1.04 and a debt-to-equity ratio of 46.56.
Consort Medical Company Profile
Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products.
Read More: What is the Rule of 72?
Receive News & Ratings for Consort Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical and related companies with MarketBeat.com's FREE daily email newsletter.